Proteomic analysis of serum and sputum analytes distinguishes controlled and poorly controlled asthmatics.

Autor: Kasaian MT; Inflammation and Immunology Research Unit, Pfizer, Cambridge, Massachusetts, USA., Lee J; Early Clinical Development, Pfizer, Cambridge, Massachusetts, USA., Brennan A; Inflammation and Immunology Research Unit, Pfizer, Cambridge, Massachusetts, USA., Danto SI; Inflammation and Immunology Research Unit, Pfizer, Cambridge, Massachusetts, USA., Black KE; Department of Medicine, University of Vermont, Burlington, Vermont, USA., Fitz L; Early Clinical Development, Pfizer, Cambridge, Massachusetts, USA., Dixon AE; Department of Medicine, University of Vermont, Burlington, Vermont, USA.
Jazyk: angličtina
Zdroj: Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology [Clin Exp Allergy] 2018 Jul; Vol. 48 (7), pp. 814-824. Date of Electronic Publication: 2018 May 15.
DOI: 10.1111/cea.13151
Abstrakt: Background: A major goal of asthma therapy is to achieve disease control, with maintenance of lung function, reduced need for rescue medication, and prevention of exacerbation. Despite current standard of care, up to 70% of patients with asthma remain poorly controlled. Analysis of serum and sputum biomarkers could offer insights into parameters associated with poor asthma control.
Objective: To identify signatures as determinants of asthma disease control, we performed proteomics using Olink proximity extension analysis.
Methods: Up to 3 longitudinal serum samples were collected from 23 controlled and 25 poorly controlled asthmatics. Nine of the controlled and 8 of the poorly controlled subjects also provided 2 longitudinal sputum samples. The study included an additional cohort of 9 subjects whose serum was collected within 48 hours of asthma exacerbation. Two separate pre-defined Proseek Multiplex panels (INF and CVDIII) were run to quantify 181 separate protein analytes in serum and sputum.
Results: Panels consisting of 9 markers in serum (CCL19, CCL25, CDCP1, CCL11, FGF21, FGF23, Flt3L, IL-10Rβ, IL-6) and 16 markers in sputum (tPA, KLK6, RETN, ADA, MMP9, Chit1, GRN, PGLYRP1, MPO, HGF, PRTN3, DNER, PI3, Chi3L1, AZU1, and OPG) distinguished controlled and poorly controlled asthmatics. The sputum analytes were consistent with a pattern of neutrophil activation associated with poor asthma control. The serum analyte profile of the exacerbation cohort resembled that of the controlled group rather than that of the poorly controlled asthmatics, possibly reflecting a therapeutic response to systemic corticosteroids.
Conclusions and Clinical Relevance: Proteomic profiles in serum and sputum distinguished controlled and poorly controlled asthmatics, and were maintained over time. Findings support a link between sputum neutrophil markers and loss of asthma control.
(© 2018 John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje